Repurposing Antihypertensive and Statin Medications for Spinal Pain

Author:

Suri Pradeep1234,Elgaeva Elizaveta E.56,Williams Frances M.K.7,Freidin Maxim B.8,Verzun Dmitrii A.56,Tsepilov Yakov A.6

Affiliation:

1. Division of Rehabilitation Care Services, VA Puget Sound Health Care System, Seattle, WA

2. Seattle Epidemiologic Research and Information Center, VA Puget Sound Health Care System, Seattle, WA

3. Clinical Learning, Evidence, and Research (CLEAR) Center, University of Washington, Seattle, WA

4. Department of Rehabilitation Medicine, University of Washington, Seattle, WA

5. Department of Natural Sciences, Novosibirsk State University, Novosibirsk, Russia

6. Laboratory of Recombination and Segregation Analysis, Institute of Cytology and Genetics, Novosibirsk, Russia

7. Department of Twin Research and Genetic Epidemiology, School of Life Course Sciences, King’s College London, London, UK

8. Department of Biology, School of Biological and Behavioural Sciences, Queen Mary University of London, UK

Abstract

Study Design. Mendelian randomization (MR) study. Objective. To examine whether antihypertensive medications (beta-blockers, calcium channel blockers, and angiotensin-converting enzyme inhibitors) and statins can be repurposed to prevent or treat spinal pain (back or neck pain). Summary of Background Data. Observational studies and a recent MR study have found associations between elevated blood pressure and a greater risk of back pain. Observational studies have found associations between hyperlipidemia and statin use and greater risk of back pain. No prior MR studies have examined the effects of antihypertensives or statins on spinal pain. Materials and Methods. This was a two-sample MR study using publicly available summary statistics from large-scale genome-wide association studies (GWAS). Sample sizes in exposure GWASs were n=757,601 (systolic blood pressure) and n=173,082 (low-density lipoprotein cholesterol), and n=1,028,947 for the outcome GWAS of spinal pain defined as health care seeking for any spinal pain-related diagnosis. Genes and cis-acting variants were identified as proxies for the drug targets of interest. MR analyses used inverse-variance weighted meta-analysis. The threshold for statistical significance after correction for multiple testing was P<0.0125. Results. No statistically significant associations of these medications with spinal pain were found. However, findings were suggestive of a protective effect of beta-blockers on spinal pain risk (odds ratio [OR] 0.84, 95% confidence interval [CI] 0.72–0.98; P=0.03), and calcium channel blockers on greater spinal pain risk (OR 1.12, 95% CI 1.02–1.24; P=0.02). Conclusions. A protective effect of beta-blockers on spinal pain was suggested in the current study, consistent with findings from observational studies of various other pain phenotypes. The detrimental effect of calcium channel blockers on spinal pain suggested in the current study must be interpreted in the context of conflicting directions of effect on nonspinal pain phenotypes in other observational studies.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Neurology (clinical),Orthopedics and Sports Medicine

Reference49 articles.

1. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017;Lancet,2017

2. Estimated research and development investment needed to bring a new medicine to market, 2009-2018;Wouters;JAMA,2020

3. The impact of patent expiry on drug prices: a systematic literature review;Vondeling;Appl Health Econ Health Policy,2018

4. Postmarket safety events among novel therapeutics approved by the US Food and Drug Administration Between 2001 and 2010;Downing;JAMA,2017

5. Amitriptyline for musculoskeletal complaints: a systematic review;van den Driest;Fam Pract,2017

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3